Immunovant to Present at Upcoming Investor Conferences
Immunovant, Inc. (IMVT) CEO, Dr. Pete Salzmann, to participate in investor conferences, including Stifel 2023 Healthcare Conference, Evercore ISI 6th Annual HealthCONx Conference, and Piper Sandler 35th Annual Healthcare Conference. The fireside chats will be webcast live and can be accessed on Immunovant's website.
11/13/2023 - 08:00 AM
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats at the following investor conferences:
Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023, at 1:50 pm ET
Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, 2023, at 5:05 pm ET
Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 11:30 am ET
The fireside chats will be webcast live and can be accessed at https://www.immunovant.com/investors/news-events . An archived webcast will be available for a limited time on Immunovant’s website.
About Immunovant, Inc. Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com .
Contact: Chau Cheng, PhD, MBA Vice President, Investor Relations Immunovant, Inc.info@immunovant.com
Jaye Bea Smalley Head, Patient Advocacy Immunovant, Inc.mediarelations@immunovant.com
What conferences will Dr. Pete Salzmann participate in?
Dr. Pete Salzmann will participate in Stifel 2023 Healthcare Conference, Evercore ISI 6th Annual HealthCONx Conference, and Piper Sandler 35th Annual Healthcare Conference.
Where can the webcast of the fireside chats be accessed?
The webcast of the fireside chats can be accessed at https://www.immunovant.com/investors/news-events.
Will the webcast be available after the live event?
An archived webcast will be available for a limited time on Immunovant’s website.
IMVT Rankings
#39 Ranked by Stock Gains
IMVT Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Finance, Financial Conglomerates, Health Technology, Biotechnology
About IMVT
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.